C-X-C motif chemokine receptor 3 ligands (CXCL9, CXCL10, CXCL11) (CXCR3 ligands)

The CXCR3 ligands, specifically CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), are pro-inflammatory chemokines primarily induced by interferon-gamma (Source: UniProt). These ligands serve as critical chemoattractants for immune cells expressing the CXCR3 receptor, including Th1-type CD4+ T cells, CD8+ cytotoxic T cells, and natural killer (NK) cells (Source: PubMed ID 21844396). In the context of oncology, tumor cells or stromal cells that express these ligands facilitate the recruitment of tumor-infiltrating lymphocytes, which is often associated with improved patient outcomes and better responses to checkpoint inhibitor therapies (Source: NIH). However, the CXCR3 axis is pleiotropic; while it generally promotes anti-tumor immunity, it can also influence tumor cell migration and angiogenesis depending on the specific receptor isoform involved (Source: PubMed ID 15153530). Therapeutic strategies targeting this axis include the use of monoclonal antibodies like Eldelumab to neutralize CXCL10 in inflammatory conditions or small molecule antagonists to block the CXCR3 receptor (Source: ClinicalTrials.gov). Conversely, in cancer therapy, researchers are investigating ways to upregulate these ligands to convert "cold" tumors into "hot," immune-responsive environments.

Other names

CXCL9CXCL10CXCL11Monokine induced by gamma interferon (MIG)Interferon gamma-induced protein 10 (IP-10)Interferon-inducible T-cell alpha chemoattractant (I-TAC)Th1-attracting chemokinesInterferon-gamma-inducible chemokines

Neutralization of chemokine ligands (e.g., CXCL10) to prevent their interaction with the CXCR3 receptor, or direct antagonism of the CXCR3 receptor to inhibit downstream signaling and chemotaxis of immune cells.